NCT01742832View on ClinicalTrials.gov

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Major Depressive Disorder
Interventions
DRUG

Vilazodone

A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.

DRUG

Citalopram

For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.

Trial Locations (1)

60615

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT01742832 - Double-Blind Treatment of Major Depressive Disorder With Vilazodone | Biotech Hunter | Biotech Hunter